Zynex (NASDAQ:ZYXI - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.09), Zacks reports. Zynex had a net margin of 2.49% and a return on equity of 13.05%.
Zynex Stock Performance
Shares of Zynex stock traded down $0.01 on Tuesday, reaching $2.23. The stock had a trading volume of 205,006 shares, compared to its average volume of 152,867. Zynex has a fifty-two week low of $1.93 and a fifty-two week high of $12.19. The stock has a market cap of $67.41 million, a P/E ratio of 14.87 and a beta of 1.09. The business's 50-day moving average price is $3.78 and its two-hundred day moving average price is $6.62. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94.
Analysts Set New Price Targets
A number of research firms have recently issued reports on ZYXI. Royal Bank of Canada reiterated a "sector perform" rating on shares of Zynex in a research note on Tuesday, April 15th. HC Wainwright dropped their price objective on shares of Zynex from $17.00 to $15.00 and set a "buy" rating on the stock in a research note on Wednesday, March 12th. Finally, LADENBURG THALM/SH SH lowered shares of Zynex from a "buy" rating to a "neutral" rating in a research note on Wednesday, March 12th.
View Our Latest Analysis on ZYXI
Insider Activity at Zynex
In other news, CFO Daniel J. Moorhead sold 10,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $7.15, for a total value of $71,500.00. Following the completion of the transaction, the chief financial officer now owns 10,050 shares of the company's stock, valued at $71,857.50. The trade was a 49.88 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 49.28% of the stock is currently owned by corporate insiders.
About Zynex
(
Get Free Report)
Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zynex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zynex wasn't on the list.
While Zynex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
